Immunartes, LLC
Chicago, IL
- UEI
- ETMGB9KR3GG4
- CAGE
- 82S33
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Sole Proprietorship
- SAM.gov registration date
- Physical address
- 400 N Aberdeen St Suite 900, Chicago, IL 60642, USA
- Website
- immunartes.com
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $657,047 |
| FY2025 | $210,985 |
| FY2024 | $2,753,572 |
| FY2023 | $622,929 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $657,047 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Advanced development of a vaccine candidate for staphylococcus aureus infection and colonization. | National Institute of Allergy and Infectious Diseases (NIH) | $5,363,612 |
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Trustees Of Boston University | 75A50122C00028 | $249,838 |
Grant awards
Similar vendors
About the company
Immunartes, LLC is a biotechnology company that specializes in the development and production of innovative immunotherapies, with a mission to harness the power of the immune system to treat and prevent diseases. It is registered as a for-profit, woman-owned small business.
Immunartes, LLC has been awarded a $11 million cost-plus-fixed-fee definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to advance development of a vaccine candidate for Staphylococcus aureus infection and colonization. This contract was awarded under the Broad Agency Announcement for Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections and Emerging Infectious Diseases, which sought proposals for advanced vaccine candidates, therapeutic products, and sequencing-based diagnostics against priority pathogens through Phase 1/2 clinical trials. The work will be performed in Chicago, Illinois over a two-year period ending in September 2024. There is no set-aside designation for this award.
Immunartes, LLC has received two federal grant awards from the National Institute of Allergy and Infectious Diseases. The first grant, awarded in January 2022, provided $496,985.47 in funding to support the development of an optimal adjuvant/antigen formulation toward a Staphylococcus aureus human vaccine. The second grant, awarded in April 2021, provided $767,532.90 in funding for the development of a vaccine for staphylococcal infections. Both grants aimed to advance Immunartes, LLC's work on developing a vaccine to prevent invasive Staphylococcus aureus infections, including those caused by antibiotic-resistant strains.
Quick answers
Is Immunartes, LLC registered in SAM.gov?
Yes. Immunartes, LLC's SAM.gov registration is active through October 8, 2027.
How much has Immunartes, LLC received in federal contracts?
Federal contracts obligated $210,985 to Immunartes, LLC in fiscal year 2025 and $4,244,533 in fiscal years 2023 through 2027.
What is Immunartes, LLC's most recent federal award?
Immunartes, LLC's most recent federal contract award is Advanced development of a vaccine candidate for staphylococcus aureus infection and colonization (75N93022C00057), from National Institute of Allergy and Infectious Diseases (NIH), on September 21, 2022.
On GovTribe
See Immunartes, LLC's full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors